T cell response to new melanoma antigen linked to relapse-free survival

Oct 20, 2008

Melanoma patients infused with a special type of tumor-fighting T cell are more likely to survive without relapse, suggests a new study by researchers in France. Their report will be published online on October 20 in the Journal of Experimental Medicine.

One treatment option for patients with late-stage melanoma involves removing natural cancer-fighting T cells from the tumor, expanding their numbers in culture dishes, and then re-infusing them into the patient. This strategy—called adoptive immunotherapy— causes tumor regression in about half the patients treated, some of whom survive for decades without relapse.

The French team, lead by Dr. Nathalie Labarriere, studied the infused cells from 30 stage III melanoma patients who had received adoptive immunotherapy between 1994 and 1998. Among the cells taken from a patient who has remained tumor-free for more than a decade, they found naturally-arising T cells that recognized a new protein, which they dubbed "meloe-1." Meloe-1, the group found, is highly expressed in melanoma cells but not in normal skin cells or in other types of cancer.

When they looked at the transferred cells from the other patients, they found meloe-1-specific T cells in 5 of the 9 patients who remained relapse-free, but in none of the 21 patients who relapsed. The association of meloe-1-specific T cells with relapse-free survival suggests that amplifying these T cells in culture may be one way to improve the efficacy of adoptive immunotherapy. The team has also succeeded in finding meloe-1 T cells in patients' circulating blood—a much more accessible source than tumor tissue.

Source: Rockefeller University

Explore further: Key milestone for brown fat research with a ground-breaking MRI scan

add to favorites email to friend print save as pdf

Related Stories

Adult stem cells found to suppress cancer while dormant

Dec 20, 2013

Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered a mechanism by which certain adult stem cells suppress their ability to initiate skin cancer during their dormant ...

Novel diagnostic method supports skin cancer therapy

Feb 15, 2013

(Phys.org)—Malignant melanoma is the most aggressive type of skin cancer. In more than 50 percent of affected patients a particular mutation plays an important role. As the life span of the patients carrying ...

Recommended for you

Gate for bacterial toxins found

12 hours ago

Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Freiburg have discovered the receptor responsible ...

User comments : 0

More news stories

New clinical trial launched for advance lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

'Chief Yahoo' David Filo returns to board

Yahoo announced the nomination of three new board members, including company co-founder David Filo, who earned the nickname and formal job title of "Chief Yahoo."

More vets turn to prosthetics to help legless pets

A 9-month-old boxer pup named Duncan barreled down a beach in Oregon, running full tilt on soft sand into YouTube history and showing more than 4 million viewers that he can revel in a good romp despite lacking ...